-
Mashup Score: 1Duchenne Muscular Dystrophy Diagnosis and Care | AAP - 28 day(s) ago
It is important to help pediatricians, other physicians, and nonphysician clinicians to diagnose and provide high standards of care for individuals with Du
Source: www.aap.orgCategories: General Medicine News, PediatricsTweet
-
Mashup Score: 4Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy - 2 month(s) ago
Delandistrogene moxeparvovec is a gene transfer therapy approved in the United States, United Arab Emirates, and Qatar for the treatment of ambulatory patients aged 4 through 5 years with a confirmed Duchenne muscular dystrophy (DMD)-causing mutation in the DMD gene. It was developed to address the underlying cause of DMD through targeted skeletal, respiratory, and cardiac muscle expression of delandistrogene moxeparvovec micro-dystrophin, an engineered, functional dystrophin protein. Drawing on clinical trial experience from Study 101 (NCT03375164), Study 102 (NCT03769116), and ENDEAVOR (Study 103; NCT04626674), we outline practical considerations for delandistrogene moxeparvovec treatment.
Source: www.pedneur.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Learn more about current and emerging gene-targeted therapies for the management of Duchenne muscular dystrophy (DMD).
Source: www.medscape.orgCategories: Latest Headlines, PediatricsTweet
-
Mashup Score: 0
Dr. Steve Hughes, CMO at Avidity, explains the mechanism of action for AOC 1044 as a Duchenne muscular dystropy (DMD) treatment.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Learn more about current and emerging gene-targeted therapies for the management of Duchenne muscular dystrophy (DMD).
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Learn more about current and emerging gene-targeted therapies for the management of Duchenne muscular dystrophy (DMD).
Source: www.medscape.orgCategories: Latest Headlines, PediatricsTweet
-
Mashup Score: 0FDA Approves First Gene Therapy for Duchenne Muscular Dystrophy - 7 month(s) ago
The US FDA has approved the gene therapy, delandistrogene moxeparvovec (Elevidys), to treat patients ages 4 through 5 years with Duchenne muscular dystrophy.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 14
Learn more about current and emerging gene-targeted therapies for the management of Duchenne muscular dystrophy (DMD).
Source: www.medscape.orgCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
How much do you know about the current approaches to diagnosing and treating Duchenne muscular dystrophy (DMD)?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0FDA Approves First Gene Therapy for Duchenne Muscular Dystrophy - 8 month(s) ago
The US FDA has approved the gene therapy, delandistrogene moxeparvovec (Elevidys), to treat patients ages 4 through 5 years with Duchenne muscular dystrophy.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
@AmerAcadPeds updated a 5-part educational series focusing on care for patients with Duchenne muscular dystrophy (DMD). Register for this free webinar to learn about emerging therapies related to caring for and managing people with #DMD. https://t.co/ywd1XNlW7J